Clinical and regulatory intelligence for Rare Disease with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Assets: 2

Relevant assets

Ipsen →

Plerixafor →

Relevant companies

G-CSF →

Recent signals(4)

ClinicalJuly 5, 2026

Long-term Study on Odevixibat Effectiveness for PFIC in South Korea Initiated

A new study has been initiated in South Korea to evaluate the long-term effectiveness and safety of odevixibat in patients with PFIC.

ClinicalJuly 4, 2026

Study on Endothelial Cell Dysfunction in Pulmonary Hypertension Launched by NIH

The NIH is conducting a study to better understand pulmonary hypertension through various diagnostic tests and treatments.

ClinicalJuly 3, 2026

Ipsen initiates trial for elafibranor in Primary Sclerosing Cholangitis

Ipsen is conducting a trial to assess the efficacy and safety of elafibranor in adult patients with Primary Sclerosing Cholangitis.

ClinicalJune 28, 2026

Plerixafor vs G-CSF Trial for WHIM Syndrome: A Comparative Study

A clinical trial is underway to compare the efficacy of plerixafor against G-CSF in treating infections in patients with WHIM syndrome.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Hepatology →

Immunology →

Pulmonary Hypertension →

Rare Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.